Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017030986> ?p ?o ?g. }
- W2017030986 endingPage "567" @default.
- W2017030986 startingPage "554" @default.
- W2017030986 abstract "Type 2 diabetes mellitus (DM) is a progressive disease. Initial therapy begins with dietary and lifestyle modifications. However, as the disease progresses, glycemic control becomes more difficult to attain, often requiring > or =1 oral antihyperglycemic medication (OAM), and finally the addition of insulin to the OAMs and insulin monotherapy.This study was designed to determine the effect of pioglitazone 30 mg plus insulin (PIO + INS) versus placebo plus insulin (PLB + INS) on glycemic control, the serum lipid profile, and selected cardiovascular risk factors in patients with type 2 DM whose disease was inadequately controlled with insulin therapy alone despite efforts to intensify such treatment.This was a 6-month, randomized, double-blind, prospective, multicenter, placebo-controlled, parallel-group study. Patients with type 2 DM and a glycosylated hemoglobin (HbA(1c)) value > or =7.5% who were using insulin (with or without OAMs) entered a 3-month insulin intensification phase to achieve blood glucose targets with insulin monotherapy. After insulin intensification, those patients with HbA(1c) values > or =7.0% were randomized to PIO + INS or PLB + INS. The primary end point was the change in HbA(1c) from baseline. Cardiovascular risk markers (highly sensitive C-reactive protein [hs CRP] and plasminogen activator inhibitor-1 [PAI-1]) were measured at baseline and end point.Of the 289 patients randomized to treatment (mean [SD] age, 58.9 [7.1] years; 164 women, 125 men), 142 received PIO + INS and 147 received PLB + INS. A total of 263 patients completed the study. After 6 months, PIO + INS reduced mean HbA(1c) (-0.69%; P < 0.002) and mean fasting plasma glucose ([FPG] -1.45 mmol/L; P < 0.002) from baseline. PLB + INS produced no significant changes in HbA(1c) or FPG. The between-treatment differences for HbA(1c) (-0.55%; P < 0.002) and FPG (-1.80 mmol/L; P < 0.002) occurred despite a reduction of insulin dose in the PIO + INS group from baseline (-0.16 U/d . kg; P < 0.002). Significant between-group differences were observed for high-density lipoprotein cholesterol (0.13 mM; P < 0.002), triglycerides (ratio of geometric mean [PIO/PLB], 0.871; P < 0.01), atherogenic index of plasma (-0.11; P < 0.002), PAI-1 (-5.10 U/mL; P < 0.001), and hs CRP (-1.47 mg/L; P < 0.05). The rate of clinical and biochemical hypoglycemia (blood glucose <2.8 mmol/L) did not differ statistically between treatment groups, but reported incidences of subjective hypoglycemia occurred more often with PIO + INS than with PLB + INS (90 vs 75; P < 0.05). Edema was more common with PIO + INS than with PLB + INS (20 vs 5 instances, respectively), as was gain (mean [SEM]) in body weight (4.05 [4.03] vs 0.20 [2.92] kg, respectively).Adding pioglitazone to insulin in these study patients with type 2 DM whose disease was inadequately controlled with insulin monotherapy further improved their glycemic control." @default.
- W2017030986 created "2016-06-24" @default.
- W2017030986 creator A5002440800 @default.
- W2017030986 creator A5013132040 @default.
- W2017030986 creator A5016547950 @default.
- W2017030986 creator A5017222417 @default.
- W2017030986 creator A5026696391 @default.
- W2017030986 creator A5048529356 @default.
- W2017030986 creator A5057037509 @default.
- W2017030986 creator A5075280104 @default.
- W2017030986 creator A5087777923 @default.
- W2017030986 creator A5091514573 @default.
- W2017030986 date "2005-05-01" @default.
- W2017030986 modified "2023-09-27" @default.
- W2017030986 title "Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study" @default.
- W2017030986 cites W1975588287 @default.
- W2017030986 cites W1982194579 @default.
- W2017030986 cites W1998221258 @default.
- W2017030986 cites W2001788016 @default.
- W2017030986 cites W2008288517 @default.
- W2017030986 cites W2014877159 @default.
- W2017030986 cites W2023383825 @default.
- W2017030986 cites W2028312640 @default.
- W2017030986 cites W2035576567 @default.
- W2017030986 cites W2039401819 @default.
- W2017030986 cites W2041144248 @default.
- W2017030986 cites W2047007084 @default.
- W2017030986 cites W2053365438 @default.
- W2017030986 cites W2063423309 @default.
- W2017030986 cites W2094083143 @default.
- W2017030986 cites W2114369760 @default.
- W2017030986 cites W2116404316 @default.
- W2017030986 cites W2123946565 @default.
- W2017030986 cites W2126781806 @default.
- W2017030986 cites W2129563195 @default.
- W2017030986 cites W2138851319 @default.
- W2017030986 cites W2154407827 @default.
- W2017030986 cites W2161086857 @default.
- W2017030986 cites W2164597700 @default.
- W2017030986 cites W2328529137 @default.
- W2017030986 cites W2769264260 @default.
- W2017030986 cites W4238251256 @default.
- W2017030986 cites W4244771114 @default.
- W2017030986 cites W4296976561 @default.
- W2017030986 doi "https://doi.org/10.1016/j.clinthera.2005.05.005" @default.
- W2017030986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15978304" @default.
- W2017030986 hasPublicationYear "2005" @default.
- W2017030986 type Work @default.
- W2017030986 sameAs 2017030986 @default.
- W2017030986 citedByCount "89" @default.
- W2017030986 countsByYear W20170309862012 @default.
- W2017030986 countsByYear W20170309862013 @default.
- W2017030986 countsByYear W20170309862015 @default.
- W2017030986 countsByYear W20170309862016 @default.
- W2017030986 countsByYear W20170309862017 @default.
- W2017030986 countsByYear W20170309862018 @default.
- W2017030986 countsByYear W20170309862019 @default.
- W2017030986 countsByYear W20170309862020 @default.
- W2017030986 crossrefType "journal-article" @default.
- W2017030986 hasAuthorship W2017030986A5002440800 @default.
- W2017030986 hasAuthorship W2017030986A5013132040 @default.
- W2017030986 hasAuthorship W2017030986A5016547950 @default.
- W2017030986 hasAuthorship W2017030986A5017222417 @default.
- W2017030986 hasAuthorship W2017030986A5026696391 @default.
- W2017030986 hasAuthorship W2017030986A5048529356 @default.
- W2017030986 hasAuthorship W2017030986A5057037509 @default.
- W2017030986 hasAuthorship W2017030986A5075280104 @default.
- W2017030986 hasAuthorship W2017030986A5087777923 @default.
- W2017030986 hasAuthorship W2017030986A5091514573 @default.
- W2017030986 hasConcept C126322002 @default.
- W2017030986 hasConcept C134018914 @default.
- W2017030986 hasConcept C142724271 @default.
- W2017030986 hasConcept C168563851 @default.
- W2017030986 hasConcept C203092338 @default.
- W2017030986 hasConcept C204787440 @default.
- W2017030986 hasConcept C27081682 @default.
- W2017030986 hasConcept C2776999253 @default.
- W2017030986 hasConcept C2777180221 @default.
- W2017030986 hasConcept C2777538456 @default.
- W2017030986 hasConcept C2778384471 @default.
- W2017030986 hasConcept C2779306644 @default.
- W2017030986 hasConcept C2780473172 @default.
- W2017030986 hasConcept C2910068830 @default.
- W2017030986 hasConcept C555293320 @default.
- W2017030986 hasConcept C71924100 @default.
- W2017030986 hasConcept C90924648 @default.
- W2017030986 hasConceptScore W2017030986C126322002 @default.
- W2017030986 hasConceptScore W2017030986C134018914 @default.
- W2017030986 hasConceptScore W2017030986C142724271 @default.
- W2017030986 hasConceptScore W2017030986C168563851 @default.
- W2017030986 hasConceptScore W2017030986C203092338 @default.
- W2017030986 hasConceptScore W2017030986C204787440 @default.
- W2017030986 hasConceptScore W2017030986C27081682 @default.
- W2017030986 hasConceptScore W2017030986C2776999253 @default.
- W2017030986 hasConceptScore W2017030986C2777180221 @default.
- W2017030986 hasConceptScore W2017030986C2777538456 @default.
- W2017030986 hasConceptScore W2017030986C2778384471 @default.
- W2017030986 hasConceptScore W2017030986C2779306644 @default.